Page last updated: 2024-11-07

tamolarizine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID146396
CHEMBL ID2074664
SCHEMBL ID331314
MeSH IDM0358263

Synonyms (16)

Synonym
nc-1100
tamolarizine
2-(4-benzhydrylpiperazin-1-yl)-1-(3,4-dimethoxyphenyl)ethanol
unii-0pg3pmk9ya
(+-)-alpha-(3,4-dimethoxyphenyl)-4-(diphenylmethyl)-1-piperazineethanol
0pg3pmk9ya ,
128229-52-7
tamolarizine [inn]
CHEMBL2074664
SCHEMBL331314
tamolarizine free base
2-(4-benzhydrylpiperazin-1-yl)-1-(3,4-dimethoxyphenyl)ethan-1-ol
Q27237062
1-(3,4-dimethoxyphenyl)-2-[4-(diphenylmethyl)piperazin-1-yl]ethan-1-ol
DTXSID20869757
AKOS040754140
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID680721TP_TRANSPORTER: increase in Rhodamine 123 intracellular accumulation (R123: 10 uM, Tamolarizine: 10 uM) in K562/DX cellsR cells, FACScan2000Japanese journal of pharmacology, Mar, Volume: 82, Issue:3
Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (35.71)18.7374
1990's7 (50.00)18.2507
2000's2 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]